

ForPatients

by Roche

Wild Type Melanoma Skin Cancer

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Trial Status
Terminated

Trial Runs In
15 Countries

Trial Identifier
NCT03273153 2016-004387-18
CO39722

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03273153 2016-004387-18 CO39722
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
